Prostate Cancer Active Surveillance

The widespread adoption of PSA screening from the early 1990s led to a dramatic increase in prostate cancer detection, with many men diagnosed with low-grade, low-volume tumors that would never cause clinical harm. Autopsy studies consistently showed that 30-40% of men over 50 harbored incidental prostate cancer, establishing that most prostate cancers are indolent. The recognition that treatment (radical prostatectomy or radiation) carried significant morbidity—urinary incontinence, erectile dysfunction, bowel complications—without clear survival benefit for low-risk disease prompted a search for alternative management strategies. The concept of 'watchful waiting' evolved into structured 'active surveillance' with serial PSA monitoring, digital rectal examination, and repeat biopsies to detect disease progression while deferring treatment for those with stable disease.

Three landmark trials established the evidence for conservative management of localized prostate cancer. The ProtecT trial (1643 patients) randomized men with PSA-detected localized prostate cancer to active monitoring, radical prostatectomy, or radiotherapy and showed no significant difference in prostate cancer-specific mortality at 10 years (approximately 1% in all groups) or 15 years. Prostatectomy and radiotherapy reduced metastasis and disease progression but at the cost of treatment-related side effects. The SPCG-4 trial showed radical prostatectomy reduced mortality compared to watchful waiting, but crucially in the pre-PSA era with clinically detected (higher risk) cancers. The PIVOT trial (731 men) showed no survival benefit of radical prostatectomy over observation for PSA-detected localized disease at 19 years, except in a subgroup with high-risk features. Together, these trials demonstrated that men with low-risk PSA-detected prostate cancer can safely defer treatment.

Multiparametric MRI (mpMRI) transformed active surveillance by enabling targeted biopsy of suspicious lesions and reducing the reliance on random systematic biopsies. The PRECISION trial (500 men) demonstrated that MRI-targeted biopsy detected more clinically significant cancers and fewer insignificant cancers than standard transrectal ultrasound-guided biopsy, improving risk stratification. For men on active surveillance, MRI enables better monitoring of disease stability and can reduce the frequency of invasive biopsies. The reclassification of Gleason 6 (Grade Group 1) prostate cancer as non-life-threatening by many pathologists—and even proposals to remove the 'cancer' label—represents a fundamental shift in how we conceptualize this disease. Genomic classifiers (Decipher, Oncotype DX, Prolaris) have added molecular risk stratification to guide surveillance versus treatment decisions.

Active surveillance is now recommended as the preferred management strategy for low-risk prostate cancer (Grade Group 1, PSA <10, clinical stage T1-T2a) by all major guidelines. The NCCN guidelines recommend active surveillance as the preferred option for very low and low-risk disease and increasingly for favorable intermediate-risk (Grade Group 2 with low volume). The EAU (European Association of Urology) guidelines strongly recommend active surveillance for Grade Group 1, stating that immediate treatment does not improve cancer-specific survival. Both guidelines incorporate MRI into the surveillance protocol, with confirmatory biopsy at 1 year and subsequent biopsies guided by MRI and PSA kinetics. The AUA/ASTRO guideline explicitly states that Grade Group 1 prostate cancer should not be routinely treated.

Active surveillance is now the dominant management strategy for low-risk prostate cancer, with uptake exceeding 60-80% at major academic centers. The ProtecT 15-year data confirmed excellent cancer-specific survival regardless of initial management, further supporting surveillance. The frontier has shifted to expanding surveillance eligibility to favorable intermediate-risk disease (Grade Group 2 with low-volume Gleason 3+4), where ongoing trials are evaluating safety. MRI-guided surveillance protocols are reducing the burden of serial biopsies while improving detection of grade progression. Focal therapy (HIFU, cryotherapy, photodynamic therapy) is emerging as a tissue-preserving treatment for men who progress on surveillance but wish to avoid whole-gland treatment, though long-term oncological data are immature. The integration of artificial intelligence into MRI interpretation and genomic classifiers into risk stratification promises to further refine patient selection for surveillance versus intervention.